Advertisement
IDXX vs SYK
Which Stock Would AI Choose? IDEXX Laboratories (IDXX) vs. Stryker (SYK) Stock Comparison
Key Takeaways
- IDEXX Laboratories (IDXX) demonstrates superior revenue growth at 14.3% year-over-year (quarterly) compared to Stryker's (SYK) 2.6%, highlighting stronger operational expansion in veterinary diagnostics.
- IDXX boasts a higher return on equity (ROE, a measure of profitability relative to shareholders' equity) of 66.2% versus SYK's 15.2%, reflecting efficient capital use.
- SYK holds a larger market capitalization of approximately $113 billion compared to IDXX's $45 billion, offering greater scale in medical devices.
- Recent market activity shows both stocks facing pressure, with SYK impacted by a Q1 cyberattack disrupting sales, while IDXX anticipates Q1 earnings growth.
- SYK trades at a lower forward price-to-earnings (P/E, stock price divided by earnings per share) ratio of 19.65 versus IDXX's 39.37, suggesting relative value.
Introduction
This stock comparison examines IDXX and SYK, two prominent players in the healthcare sector—veterinary diagnostics for IDEXX Laboratories and medical technology devices for Stryker. Investors seeking exposure to animal health innovation or human medical equipment may find value in analyzing their relative performance. With pet ownership trends driving demand and medtech recovery amid supply challenges, this analysis highlights recent momentum, financial metrics, and market positioning to aid informed decision-making in a volatile environment. Traders focused on growth versus value trade-offs will benefit from these insights.
IDXX Overview and Recent Performance
IDEXX Laboratories (IDXX) specializes in veterinary diagnostics, practice management software, and water testing solutions, primarily serving the companion animal market. The stock has traded around $567 in recent sessions, down from 52-week highs near $770 amid broader market rotations away from high-growth names. Key metrics include a trailing P/E of 43.28, market cap of $45 billion, and robust quarterly revenue growth of 14.3% year-over-year. Sentiment reflects anticipation for Q1 2026 earnings on May 5, with projections for $1.12 billion in revenue (up 11.9%) and $3.42 EPS, supported by steady demand in pet healthcare. Recent weeks have seen pressure from a softened 2026 outlook, contributing to a pullback, though year-to-date gains stand at about 16%.
SYK Overview and Recent Performance
Stryker Corporation (SYK) is a global leader in medical technologies, including orthopaedics, surgical equipment, and neurotechnology. Shares hover near $295, close to 52-week lows of $294.55 after retreating from highs above $404. The company reports a trailing P/E of 35.09, market cap of $113 billion, and Q1 2026 revenue of $6.02 billion (up 2.6% year-over-year but below estimates). A late-quarter cyberattack hampered production and sales, leading to an adjusted EPS miss at $2.60 (down 8.5% year-over-year). Despite this, management reaffirmed full-year guidance for 8-9.5% organic sales growth. Recent performance reflects heightened volatility, with one-month declines around 11%.
Trending AI Robots
Tickeron's Trending AI Robots page showcases 25 top-performing AI trading bots curated from over 350 available bots that trade thousands of tickers across various strategies. These bots employ diverse approaches, including swing trading, short-term signals, and sector-specific plays in areas like semiconductors, industrials, and ETFs. Performance highlights include annualized returns ranging from 23.53% to 163.10%, win rates of 51.30% to 88.33%, and profit factors up to 11.70. Trade durations vary from 1 day to 49 days, with profit-to-drawdown ratios reaching 17.02. Optimized for current market conditions, they offer real-time signals for copy trading. Traders can explore these bots to align with their risk tolerance and timeframes.
Head-to-Head Comparison
IDXX focuses on recurring revenue from diagnostics in the growing pet sector, contrasting SYK's capital-intensive medical device model reliant on procedures and M&A (mergers and acquisitions). Growth drivers for IDXX include pet ownership trends, while SYK benefits from aging populations and elective surgeries. Recent momentum favors neither decisively, with IDXX showing steadier trends but elevated valuations (PEG ratio 3.95 vs. 1.40) and SYK pressured by operational risks like cyber disruptions. Risk factors include IDXX's consumer cyclical exposure and SYK's supply chain vulnerabilities. Market sentiment tilts toward IDXX for profitability but SYK for scale and recovery potential.
Tickeron AI Verdict
Tickeron's AI currently leans toward IDXX based on consistent growth metrics, superior ROE, and stable trend positioning in recent market activity, despite higher multiples. SYK offers compelling value post-setback with reaffirmed guidance, but elevated short-term risks temper enthusiasm. This probabilistic edge for IDXX reflects observable catalysts like earnings anticipation over cyber recovery uncertainties.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDXX is a StrongBuy and SYK is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IDXX’s FA Score shows that 1 FA rating(s) are green whileSYK’s FA Score has 1 green FA rating(s).
- IDXX’s FA Score: 1 green, 4 red.
- SYK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IDXX’s TA Score shows that 5 TA indicator(s) are bullish while SYK’s TA Score has 3 bullish TA indicator(s).
- IDXX’s TA Score: 5 bullish, 4 bearish.
- SYK’s TA Score: 3 bullish, 4 bearish.
Price Growth
IDXX (@Medical Specialties) experienced а -5.53% price change this week, while SYK (@Medical/Nursing Services) price change was -1.06% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.78%. For the same industry, the average monthly price growth was +3.12%, and the average quarterly price growth was -3.78%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.22%. For the same industry, the average monthly price growth was -3.84%, and the average quarterly price growth was -16.30%.
Reported Earning Dates
IDXX is expected to report earnings on Aug 04, 2026.
SYK is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Medical Specialties (+0.78% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
@Medical/Nursing Services (-0.22% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
| IDXX | SYK | IDXX / SYK | |
| Capitalization | 42.7B | 119B | 36% |
| EBITDA | 1.56B | 6.44B | 24% |
| Gain YTD | -19.987 | -13.075 | 153% |
| P/E Ratio | 40.16 | 35.27 | 114% |
| Revenue | 4.45B | 25.3B | 18% |
| Total Cash | 201M | 2.97B | 7% |
| Total Debt | 1.11B | 14.7B | 8% |
IDXX | SYK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 65 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 82 Overvalued | 9 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 69 | |
SMR RATING 1..100 | 16 | 57 | |
PRICE GROWTH RATING 1..100 | 58 | 62 | |
P/E GROWTH RATING 1..100 | 69 | 80 | |
SEASONALITY SCORE 1..100 | 85 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYK's Valuation (9) in the Medical Specialties industry is significantly better than the same rating for IDXX (82). This means that SYK’s stock grew significantly faster than IDXX’s over the last 12 months.
SYK's Profit vs Risk Rating (69) in the Medical Specialties industry is in the same range as IDXX (100). This means that SYK’s stock grew similarly to IDXX’s over the last 12 months.
IDXX's SMR Rating (16) in the Medical Specialties industry is somewhat better than the same rating for SYK (57). This means that IDXX’s stock grew somewhat faster than SYK’s over the last 12 months.
IDXX's Price Growth Rating (58) in the Medical Specialties industry is in the same range as SYK (62). This means that IDXX’s stock grew similarly to SYK’s over the last 12 months.
IDXX's P/E Growth Rating (69) in the Medical Specialties industry is in the same range as SYK (80). This means that IDXX’s stock grew similarly to SYK’s over the last 12 months.
| IDXX | SYK | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 64% | 2 days ago 55% |
| Momentum ODDS (%) | 2 days ago 65% | 2 days ago 57% |
| MACD ODDS (%) | 2 days ago 62% | 2 days ago 52% |
| TrendWeek ODDS (%) | 2 days ago 70% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 72% | 2 days ago 52% |
| Advances ODDS (%) | 8 days ago 59% | 19 days ago 55% |
| Declines ODDS (%) | 16 days ago 70% | 13 days ago 53% |
| BollingerBands ODDS (%) | 2 days ago 62% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 53% | 2 days ago 47% |
Advertisement
SYK and
Correlation & Price change
A.I.dvisor indicates that over the last year, SYK has been loosely correlated with ISRG. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if SYK jumps, then ISRG could also see price increases.